Ameliorative role of Omega-3 fatty acids and Vitamin E against Carbamazepine induced Hepatoxicity in Rats
DOI:
https://doi.org/10.32947/ajps.v26i2.1359Keywords:
Drug induced liver injury, Carbamazepine, omega-3, vitamin E, Nrf2, HistopathologyAbstract
Background: Carbamazepine has been utilized to treat epilepsy and neuralgic conditions. Drug-induced liver injury triggered by Carbamazepine. Drug-induced liver injury from Carbamazepine consequently leads to liver failure. Existing research found that Omega-3 fatty acids and vitamin E known for their cytoprotective properties, and anti-inflammatory characteristics but their protective role against Carbamazepine induced liver injury yield inconclusive results.
Objective: To investigate closely omega-3 and vitamin E potential protective effect against carbamazepine hepatoxicity in rats.
Materials & Methods: Group 1: control received distilled water alone; Group 2: Treated with carbamazepine; Group 3: Treated with carbamazepine then followed by omega-3; Group 4: Treated with carbamazepine then followed by vitamin E; Group 5: Treated with carbamazepine then followed by a combination of omega-3 plus vitamin E experimental period lasted for fourteen days, at the end of the study all rats anesthetized. The liver tissue was dissected from each rat, part of liver tissue was used to evaluate Nuclear Factor Erythroid 2-Related Factor 2 gene expression and histological analysis using H&E stain was performed on the other part of liver tissue after formalin fixation (10%).
Results: The Nuclear Factor Erythroid 2-Related Factor 2 gene expression showed significant increase in treated groups 3,4,5 versus Carbamazepine group which indicate protective cellular response to restore redox balance. Histopathological evaluations were conducted that liver tissue architecture and cellular integrity showed normal liver appearance, the hepatocytes and sinusoids looked normal in Group 3,4,5 in comparison to Carbamazepine group that showed severe congestion of sinusoids, and signs of liver damage indicate that liver tissue changes had occurred.
Conclusion: Omega -3 and vitamin E alleviated Carbamazepine hepatoxicity through elevation antioxidant Nuclear Factor Erythroid 2-Related Factor 2 gene expression and maintenance integrity of liver tissue.
References
1. Schwarz A, Strakos C and Weihrich R. A Brief Review on Carbamazepine – History, Pharmacological Properties and Environmental Impact. Insights in Chemistry and Biochemistry. 2021;1(4):1-4.
2. Stevens R, Konsil J, Dechasathian S, David Mason TH, Stevens RE. Reanalysis of carbamazepine and carbamazepine- epoxide pharmacokinetics after multiple dosing of extended release formulation Reanalysis of Carbamazepine and Carbamazepine-Epoxide Pharmacokinetics after Multiple Dosing of Extended Release Formulations . J Pharm Pharm Sci . 2002;5(2):169-75
3. Yin X, Cicali B, Rodriguez-Vera L, Lukacova V, Cristofoletti R, Schmidt S. Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes. Pharmaceutics. 2024;16(6): 737.
4. Thorn CF, Leckband SG, Kelsoe J, Steven Leeder J, Müller DJ, Klein TE, et al. PharmGKB summary: Carbamazepine pathway. Pharmacogenet Genomics. 2011;21(12):906–10.
5. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug induced liver injury–a 2023 update. Journal of Toxicology and Environmental Health - Part B. 2023;26(8):442-467.
6. Korver S, Bowen J, Pearson K, Gonzalez RJ, French N, Park K, et al. The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Archives of Toxicology. 2021; 95:3435–3448.
7. Maris BR, Grama A, Pop TL. Drug-Induced Liver Injury—Pharmacological Spectrum Among Children. International Journal of Molecular Sciences. International Journal of Molecular. Sciences. 2025;26: 2006.
8. Björnsson ES. The Epidemiology of Newly Recognized Causes of Drug- Induced Liver Injury: An Update. Pharmaceuticals (Basel). 2024;17(4):520.
9. Mohammed YH, Hassan AF. Evaluation the anti-inflammatory effect of Omega 369 against acetaminophen-induced hepatotoxicity in mice. Pharmacia. 2023;70(3):419–24.
10. Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver international. 2022;42(9):1999-2014
11. Kobayashi T, Iwaki M, Nogami A, Yoneda M. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM. Journal of Clinical and Translational Hepatology. 2023;11(5):1239–1245
12. Babich M, De R, Guerra L, Daniel T, Adewuyi O. Drug-Induced Liver Injury (DILI): A Practical Review. PRACTICAL GASTROENTEROLOGY .2024.
13. Zhou Y, Wang J, Zhang D, Liu J, Wu Q, Chen J, et al. Mechanism of drug- induced liver injury and hepatoprotective effects of natural drugs. Chinese Medicine. 2021;16:135.
14. Keshari AC, Thitame SN, Aher AA, Keshari UC. Drug-Induced Liver Injury: Mechanisms, Diagnosis, and Management: A Review. J Pharm Bioallied Sci .2025;17(Suppl 1): S55–8.
15. Patted PG, Masareddy RS, Patil AS, Kanabargi RR, Bhat CT. Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits. Future J Pharm Sci. 2024;10:94.
16. Vell MS, Creasy KT, Scorletti E, Seeling KS, Hehl L, Rendel MD, et al. Omega-3 intake is associated with liver disease protection. Front Public Health. 2023; 11:1192099.
17. Hassani HK, Hummadi YA, Al-Mugdadi HSF. Protective Effect of Omega-3 and the Potential of Toll-like Receptor Gene Expression in Rats with Doxorubicin-induced Cardiac Toxicity. Tropical Journal of Natural Product Research. 2023;7(2):2358–61.
18. Al-Dabbagh ASM, Mshemish BAR, Al-Mugdadi SFH. Investigating the potential protective effects of omega-3 against doxorubicin-induced renal injury in rats through modification of antioxidant markers. Immunopathologia Persa. 2024 :e41707
19. Parker HM, Cohn JS, O’connor HT, Garg ML, Caterson ID, George J, et al. Effect of fish oil supplementation on hepatic and visceral fat in overweight men: A randomized controlled trial. Nutrients.2019;11(2):475.
20. Al-Mugdadi SFH, Elewi IH, Shafeeq ZF, Abd Ali MM, Hammadi SQ, Abd-Alraheem MS. Effect of Omega-3 Fatty Acids on the Lipid Profile in Rats induced-acute cardiotoxicity by doxorubicin. Journal of Neonatal Surgery. 2025; 14 (1s):1227-1234.
21. Mohd Zaffarin AS, Ng SF, Ng MH, Hassan H, Alias E. Pharmacology and pharmacokinetics of Vitamin E: Nano formulations to enhance bioavailability. International Journal of Nanomedicine. 2020; 15:9961–9974 .
22. Traber MG. Current evidence of the role of vitamin E in prolonging a healthy life. Redox Experimental Medicine. 2023:1-36.
23. Traber MG. Vitamin E. Advances in Nutrition. 2021;12 (Issue 3):1047–1048.
24. Okolonkwo et al.. “Evaluating the Impact of Vitamin E Treatment on Paraquat Induced Toxicity in Liver”. Current Research in Interdisciplinary Studies. 2023; 2(2): 6 – 11.
25. Al Attar F M N, Numan I T, Al-Mugdadi, S. F. H.. Assessment of the protective effects of omega-3 fatty acid and vitamin E against carbamazepine hepatotoxicity in rats by alteration of liver enzymes, antioxidant and inflammatory markers. Pharmaceutical Sciences. 2025; 31(4): 491–496.
26. Zhou, J, Zheng, Q & Chen, Z. The Nrf2 Pathway in Liver Diseases. Frontiers in cell and developmental biology. 2022; 10: 826204.
27. El-Mowafy AM, Abdel-Aziz AA, Abdel-Dayem MA. Novel protection by Omega-3-FAs (DHA or EPA) against carbamazepine’s liver-injury: differential suppression of oxidative- stress and inflammatory markers, and the influence on carbamazepine-clearance. Clinical Nutrition Open Science. 2022;42: 14–26.
28. Suvarna KS, Layton C, Bancroft JD. Bancroft’s theory and practice of histological techniques E-Book. 8th Edition. Elsevier health sciences; 2018.
29. Rahman MA, Sultana N, Ayman U, Bhakta S, Afrose M, Afrin M, et al. Alcoholic fixation over formalin fixation: A new, safer option for morphologic and molecular analysis of tissues. Saudi J Biol Sci. 2022;29(1):175–82.
30. Rubbia-Brandt L., Audard V, Sartoretti P, Roth AD, Brezault C, et.al. Histological features and severity of oxaliplatin-induced liver injury and clinical associations. Journal of Clinical Oncology. 2004; 22(6):1158–1169.
31. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clinical and Experimental Medicine. Springer Science and Business Media Deutschland GmbH; 2023;23(2) : 273–285.
32. Jadeja RN, Upadhyay KK, Devkar RV, Khurana S. Naturally Occurring Nrf2 Activators: Potential in Treatment of Liver Injury. Oxid Med Cell Longev. 2016; 2016:3453926.
33. Saleh DO, Mahmoud SS, Hassan A , Sanad EF. Doxorubicin-induced hepatic toxicity in rats: Mechanistic protective role of Omega-3 fatty acids through Nrf2/HO-1 activation and PI3K/Akt/GSK-3β axis modulation. Saudi Journal of Biological Sciences. 2022; 29(7): 103308.
34. Fang J, Yin H, Yang Z, Tan M, Wang F, Chen K , Zuo Z, et.al. Vitamin E protects against cadmium-induced sub-chronic liver injury associated with the inhibition of oxidative stress and activation of Nrf2 pathway. Ecotoxicology and environmental safety. 2021; 208: 111610.
35. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, et al. Metabolic activation and inflammation reactions involved in carbamazepine- induced liver injury. Toxicological Sciences. 2012;130(1):4–16.
36. Ibrahim MA, Ibrahim HM, Mohamed AA, Tammam HG. Vitamin E supplementation ameliorates the hepatotoxicity induced by Tramadol: toxicological, histological and immunohistochemical study. Toxicol Mech Methods. 2020;30(3):177–88.
37. Lotfi A, Rafie SM, Hesaraki S, Amini K. Protective Effects of Coadministration of the Vitamin E and Omega-3 on Doxorubicin-Induced Hepatotoxicity in Mice. International journal of cancer Managment.2022;15(10): e121766.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Furkan Majid AL Attar, intesar tarik numan, Suhad Faisal Hatem Al- Mugdadi
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
